Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer
about
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerControlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysisRecent insights into the implications of metabolism in plasmacytoid dendritic cell innate functions: Potential ways to control these functionsThe dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinomaFractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells.Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma.Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors.Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients.Oxidative dna damage of lymphocytes in peripheral blood and ascites in cancer patients.Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3(+) regulatory T cells and are associated with poor prognosis in breast cancer patients.The multifaceted biology of plasmacytoid dendritic cells.Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cellsRole of dendritic cells in the regulation of antitumor immunityImmune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.Aiming to immune elimination of ovarian cancer stem cellsTherapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancerCirculating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection.Targeting regulatory T cells.Tumor associated regulatory dendritic cells.Dendritic cell immunotherapy in ovarian cancer.What are the molecules involved in regulatory T-cells induction by dendritic cells in cancer?Deciphering and reversing tumor immune suppression.Clinical evaluation of systemic and local immune responses in cancer: time for integration.Neuropilin 1: function and therapeutic potential in cancer.Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition.Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy.Dendritic Cells in the Context of Human Tumors: Biology and Experimental Tools.HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells.Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells.Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.Functional OCT4-specific CD4(+) and CD8(+) T cells in healthy controls and ovarian cancer patients.Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis.Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.Disease-Associated Plasmacytoid Dendritic Cells.Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter.Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells.Self-Renewal and Toll-like Receptor Signaling Sustain Exhausted Plasmacytoid Dendritic Cells during Chronic Viral Infection.The MEK1/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells.Cancer Vaccines in Ovarian Cancer: How Can We Improve?
P2860
Q26996829-D86742A7-1BE2-46E9-8CA1-D3BA31CD6FECQ28281796-143B19A6-287B-46C2-A90E-6D3266BF4E28Q30252210-7168ED2E-ABBA-4058-92BC-DDC92DB6C189Q30317628-6005D4FF-74FD-4BE8-B747-156FA93F81A1Q35122843-1ACE35A9-CA9E-4626-BEF6-3C5819126C62Q35683268-DA697252-B1CF-4167-BD55-05A7BD26C8E9Q35763478-214D1628-73DE-4CA1-9EE9-6CF99AFA357EQ35798826-91EFD487-F219-487D-8BE5-3241227F2225Q36057482-FA20D9DC-BC5A-4CEB-B099-1167108DD324Q36145315-6C1E165F-3484-4BFF-B128-5045B55BDADEQ36643627-A52D1B87-952F-4002-B3F4-EA44A3BFD41BQ36731249-57824261-E411-4F66-80BD-105C678FEB85Q36839509-81316232-89B4-4A38-8141-FC019C724415Q36845842-D9B90268-6135-4F0E-8850-A9A3006B53CDQ37224568-5F02C721-D3B1-49F0-A5F6-A1AF21CD4F85Q37266548-80B68E0B-8DCA-41CE-9E01-C0108F1870C1Q37365673-84C06806-04E7-407A-A188-12193B12F8CAQ37720298-B1BC53FA-5DE4-4849-A345-82F177F4A2EEQ37983467-FBD96891-3A62-4C0E-BFF6-855EC8991E2CQ37993359-95521BFB-2625-4023-97FF-EE6BF877995EQ38069183-61532C17-187E-4291-B74E-C12957976F4BQ38114070-79169AF7-24F3-429B-B01B-EEF42C559057Q38124437-1FA6341D-EAB7-401C-A74A-7782F6DA5BEDQ38150174-6F6014EC-B0D3-458B-B96C-C02EE187919BQ38165001-B4D94567-39AE-4F96-A659-9E77CDB862A5Q38172849-8F4A000D-12AC-4DE7-8895-66A9D217058CQ38206571-5FC3C8D6-B5CB-4510-B296-E85089F1ADCCQ38786002-AE114940-C60A-4FB3-8F77-12C4DCCBD5B6Q38930365-8D62259F-B8CE-4B8E-9E5B-F0971C591365Q39302053-2ACC88A4-F174-4EC9-864C-4B13A7ADF2E4Q41006936-A6CA2D3C-2333-47D6-AF36-0149E3CE3459Q41220323-9AA18961-3309-4A44-A32C-5073BC1345BDQ42103971-B26C1218-25A8-4467-AA8F-473567F3BCFAQ42375254-6F62035D-A2E2-4890-8F3C-95F505DFC409Q43930865-9D7628B2-45EE-4939-855A-60F857CC4D52Q46829537-6E637CF9-A5BB-4AE0-8324-E7F8DE644FE3Q51832626-580E9545-DEA2-4AF5-A8D5-22890B14F350Q52580162-DD790166-3222-4AAD-922E-DFDEEA8BDE3BQ54121472-B802638F-5E2C-4619-B62B-A5F9464ADF94Q54385315-0167E180-E4F1-46DF-9B0B-894F7A938D84
P2860
Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer
description
im Juni 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 22 June 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2011
@uk
name
Quantitative and Functional Al ...... ne Tolerance in Ovarian Cancer
@en
Quantitative and Functional Al ...... ne Tolerance in Ovarian Cancer
@nl
type
label
Quantitative and Functional Al ...... ne Tolerance in Ovarian Cancer
@en
Quantitative and Functional Al ...... ne Tolerance in Ovarian Cancer
@nl
prefLabel
Quantitative and Functional Al ...... ne Tolerance in Ovarian Cancer
@en
Quantitative and Functional Al ...... ne Tolerance in Ovarian Cancer
@nl
P2093
P50
P1433
P1476
Quantitative and functional al ...... ne tolerance in ovarian cancer
@en
P2093
Agathe Bajard
Alexandre Cassignol
Christine Ménétrier-Caux
François Mithieux
Isabelle Durand
Isabelle Ray-Coquard
Isabelle Treilleux
Jean-Damien Combes
Julien Faget
Michael Gobert
P304
P356
10.1158/0008-5472.CAN-11-0367
P407
P577
2011-06-22T00:00:00Z